Oncopharmpod

  • Autor: Vários
  • Narrador: Vários
  • Editora: Podcast
  • Duração: 105:24:50
  • Mais informações

Informações:

Sinopse

Oncology Pharmacist & Educator. Talking all things #oncopharm

Episódios

  • AMPLIFY

    20/02/2025 Duração: 17min

    We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL. Link: DOI: 10.1056/NEJMoa2409804

  • OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma post-CAR-T

    13/02/2025 Duração: 12min

    Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports. 1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-fatal-tumor-lysis-syndrome-in-a-patient-with-acute-myeloid-leukemia-receiving-azacitidine-and-venetoclax-without-a-ramp-up-schedule-a-case-report 2. CD4+ T-cell lymphoma harboring a CAR integration into TP53: https://www.nejm.org/doi/full/10.1056/NEJMoa2411507

  • [Re-release] Rituximab

    06/02/2025 Duração: 18min

    Dipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?

  • Acalabrutinb + BR and sotorasib + panitumumab

    30/01/2025 Duração: 08min

    FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

  • Datoptamab deruxtecan

    22/01/2025 Duração: 18min

    Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.

  • Dex Dosing in MM, Tec-Tal, & postMONARCH

    16/01/2025 Duração: 12min

    HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBR Dexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939 Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939 postMONARCH: https://doi.org/10.1200/JCO-24-02086

  • Breakwater, Ensartinib, & SC Nivo

    09/01/2025 Duração: 10min

    We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

  • The Accelerated Approval Pathway

    02/01/2025 Duração: 13min

    Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer. Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5

  • 2024 New Drug Review

    19/12/2024 Duração: 18min

    Looking back at new approvals from 2024 - what to keep, re-gift, or return? And yes, as soon as this was recorded 2 new drugs were approved.

  • A Feast Of Updates

    12/12/2024 Duração: 17min

    Lots of recent clinical trial updates to discuss: AQUILA: Daratumumab for high-risk smoldering multiple myeloma Checkmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancer DESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBC ARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastric/GEJ cancer HELEN-006: Neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab vs. TCHP in breast cancer SONIA: finally published!

  • Zenocutuzumab

    05/12/2024 Duração: 12min

    A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.

  • Revumenib

    21/11/2024 Duração: 14min

    The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias. Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265

  • Anthracycline Use In Breast Cancer

    14/11/2024 Duração: 09min

    A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-01916 10-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836 Bonus - Practical Guide for Testing for Pharmacogenomics: https://doi.org/10.1200/OP.24.00191

  • SWISH

    07/11/2024 Duração: 09min

    Reviewing the data to support use of dexamethasone solution mouthwash for PIK3/AKT/mTOR inhibitor-induced stomatitis, caused by drugs like everolimus, alpelisib, capivasertib, & inavolisib. SWISH: https://doi.org/10.1016/s1470-2045(17)30109-2 Alliance MIST Trial: https://doi.org/10.1053/j.seminoncol.2023.01.001

  • Zolbetuximab

    31/10/2024 Duração: 19min

    The first Cldn 18.2 targeting monoclonal antibody has been improved. Let's talk about it!

  • S1826 & INTERLACE

    24/10/2024 Duração: 22min

    Discussing two excellent articles from earlier this month. S1826: N-AVD vs. Bv-AVD (DOI: 10.1056/NEJMoa2405888) & INTERLACE: induction chemo prior to concurrent cisplatin/RT in locally advanced cervical cancer (DOI: https://doi.org/10.1016/S0140-6736(24)01438-7)

  • Inavolisib

    17/10/2024 Duração: 16min

    A new PIK3Ca inhibitor is approved for breast cancer.

  • Autumnal (2024) AML Updates

    10/10/2024 Duração: 13min

    Reviewing 3 recent AML publications Double-Dauno (90 mg/m2 vs. 60 mg/m2): https://doi.org/10.1200/JCO.24.00235 AML60+ Risk Stratification: https://doi.org/10.1200/JCO.23.02631 Decitabine-Ven as bridge to Allo HSCT: https://doi.org/10.1016/S2352-3026(24)00241-2

  • MSI-High Rectal Cancer Treatment

    03/10/2024 Duração: 10min

    MSI-high/MMRd rectal cancer treatment guidelines are being re-written. A brief synopsis of why treatment guidelines are changing so quickly in this space. Also, listeners helped out in explaining the ribociclib storage & stability change. Hint: https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-latest-regulatory-standards-ebc-end-q2

  • NATALEE + a slew of FDA updates

    26/09/2024 Duração: 16min

    FDA has been busy the last week approving: -ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement -osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC -amivantamab + chemotherapy following progression on osimertinib (Mariposa-2) -a subcutaneous formulation of atezolizumab -isatuximab + VRD for multiple myeloma -pembrolizumab + chemotherapy for metastatic pleural mesothelioma

página 1 de 19
Experimente 7 dias grátis

Experimente 7 dias grátis

  • Acesso ilimitado a todo o conteúdo da plataforma.
  • Mais de 30 mil títulos, entre audiobooks, ebooks, podcasts, séries, documentários e notícias.
  • Narração dos audiolivros feita por profissionais, entre atores, locutores e até mesmo os próprios autores.
Experimente 7 dias Grátis Promoção válida para novos usuários. Após 7 dias, será cobrado valor integral. Cancele quando quiser.

Compartilhar